

Medlab Clinical Ltd

04:14 16 Apr 2019

Medlab Clinical collaborates with Chronic Pain Australia

Medlab Clinical Ltd (ASX:MDC) has entered into a collaborative agreement with Chronic Pain Australia to promote the education of medicinal cannabis to doctors and patients.

Specifically, to people living with chronic pain and their relevant healthcare providers.

The roll-out commences this month.

READ: Medlab CEO presents clinical NanaBis update to medical practitioners

Medlab's CEO Dr Sean Hall said: "We openly welcome this alliance with Chronic Pain Australia, we understand that pain management has to extend beyond opioids, their derivatives, and lifestyle management; new therapies such as NanaBis™ equate to more options, and together we can work on better patient outcomes."

Chronic Pain Australia is a not-for-profit consumer-lead organisation dedicated to reducing health and social barriers faced by people living with chronic pain.

It supports over 35,000 people living with chronic pain each month and has partnered with the Australian Pain Society and Faculty of Pain Medicine to develop Australia's first National Pain Strategy.

NanaBis™ in clinical trial at Royal North Shore Hospital

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidia™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidia™ has a 18:2 ratio of CBD:THC.

NanaBis™ is currently in clinical trial at Royal North Shore Hospital.

Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Proactive caught up with Medlab last month to get an update on the company, including NRGBiotic™, a probiotic.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: A\$0.39

Market Cap: A\$82.3M

1 Year Share Price Graph



Share Information

Code: MDC

Listing: ASX

52 week High Low
A\$0.57 A\$0.34

Sector: Cannabis

Website: www.medlab.co

Company Synopsis:

Medlab Clinical Ltd (ASX:MDC) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.